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 i g  h  l  i  g  h  t  s
MSCs  can  be delivered  to injured  spinal  cord  through  use of a ﬁbrin  scaffold.
Scaffold-delivered  MSCs  form  longitudinally-aligned  layers  over  the  lesion  site.
Regenerating  axons enter  scaffold-delivered  grafts  and  grow  longitudinally.
MSCs  delivered  via  injection  orient  perpendicular  to the  plane  of the  spinal  cord.
Regenerating  axons in  injected  grafts  grow  perpendicular  to  the  plane  of the  cord.
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a  b  s  t  r  a  c  t
Mesenchymal  stromal  cells  (MSCs)  have  been  shown  to promote  healing  and  regeneration  in a number
of  CNS  injury  models  and  therefore  there  is  much  interest  in  the  clinical  use  of  these  cells.  For  spinal
cord  injuries,  a  standard  delivery  method  for MSCs  is intraspinal  injection,  but this  can  result  in addi-
tional  injury  and  provides  little  control  over  how  the  cells  integrate  into  the  tissue.  The  present  study
examines  the  use  of  a  novel  ﬁbrin  scaffold  as  a new  method  of  delivering  MSCs  to injured  spinal  cord.
Use  of  the  ﬁbrin  scaffold  resulted  in  the formation  of  longitudinally-aligned  layers  of  MSCs  growing  overesenchymal stromal cells
ell scaffold
ibrin
the  spinal  cord  lesion  site.  Host  neurites  were  able  to migrate  into  this  MSC  architecture  and  grow  longi-
tudinally.  The  length  of  the  MSC  bridge  corresponded  to  the length  of  the  ﬁbrin  scaffold.  MSCs  that  were
delivered  via  intraspinal  injection  were mainly  oriented  perpendicular  to the plane  of the spinal  cord
and  remained  largely  restricted  to the  lesion  site.  Host  neurites  within  the  injected  MSC  graft  were  also
oriented  perpendicular  to  the plane  of the  spinal  cord.
©  2014  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the  CC  BY
license  (http://creativecommons.org/licenses/by/3.0/).. Introduction
The failure of axons to regrow following spinal cord injury has
een attributed to a number of factors; these include the hostile
nvironment, the presence of inhibitory molecules, the absence of a
ermissive substrate through which regenerating axons can project
Abbreviations: MSCs, mesenchymal stromal cells; EDC, N-(3-dimethyl-
minopropyl)-N-ethyl-carbodiimide hydrochloride; NHS, N-hydroxysuccinimide.
∗ Corresponding author. Tel.: +44 1223331160; fax: +44 1223331174.
E-mail address: krgm2@cam.ac.uk (K.R. Martin).
1 Both authors contributed equally to this manuscript.
ttp://dx.doi.org/10.1016/j.neulet.2014.03.023
304-3940/© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access across the lesion, and insufﬁcient trophic support [1]. Transplan-
tation of bone marrow-derived mesenchymal stromal cells (MSCs)
may  help to overcome some of these factors. A major advantage of
using MSCs over most other cell types is that MSCs can be autolo-
gously sourced, rendering them non-immunogenic. MSCs are also
easily expanded ex vivo, making them attractive for clinical use.
MSCs have been shown to have a beneﬁcial effect in a variety of CNS
injury models, including traumatic brain injury [2], stroke [3], and
spinal cord injury [1,4–10]. The cells are known to release a range
of trophic factors, such as BDNF, NGF, VEGF, FGF-2, TGF-, IGF-1,
brain natriuretic peptide, and stromal cell-derived factor-1 [11];
these factors can contribute to neuroprotection, stimulate neovas-
cularisation, and facilitate wound repair. There is also evidence
article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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hat MSCs induce axonal sprouting and remyelination [12] as well
s modulate the immune response [13,14], however, the precise
echanisms by which MSCs promote healing remain unclear.
A number of studies have examined the use of MSCs in acute or
hronic injury models of the spinal cord. In both models, MSCs have
een shown to promote signiﬁcant functional recovery [4–6,9]. All
f these studies used intraspinal injection as the delivery method
or the cells. This type of injection has been shown to be far more
ffective than intravenous administration for chronic spinal cord
njuries [15]. However, intraspinal injection may  not be the opti-
um  approach for delivering cells to the spinal cord [16]. Previous
esearch in the eye has shown that using a cell scaffold can improve
ell survival and integration after transplantation [17]. A scaffold
rovides the cells with an adherent substrate and may  help to pre-
ent anoikis [18]. The focus of this study was to investigate a novel
brin scaffold as a new method of delivering cells. MSCs growing
s a single layer on top of a ﬁbrin sheet were laid over top of the
njured spinal cord.
. Methods and materials
.1. Manufacture of EDC-ﬁbrin scaffold
7.8 mg  of Tisseel powder (Baxter Healthcare Ltd.), contain-
ng 4.8 mg  of human ﬁbrinogen, was dissolved in 27 L of
protinin (Baxter Healthcare Ltd.). A solution of EDC (N-(3-
imethylaminopropyl)-N-ethyl-carbodiimide hydrochloride;
igma–Aldrich) and NHS (N-hydroxysuccinimide; Sigma–Aldrich)
as then prepared: 62.5 L of dH2O was added to a mixture
f 7.5 mg  of NHS and 12.5 mg  of EDC. 6 L of the EDC/NHS
olution was then physically mixed into the ﬁbrinogen solu-
ion using a micropipette tip for approximately two minutes
ntil the gel began to solidify. Next, the ball of ﬁbrinogen was
ompressed between two glass plates and allowed to set for
5 min  at room temperature. PBS was then added to the ﬁbrin
heet to rehydrate it before moving it to a 50 mL  plastic tube
ontaining PBS. The ﬁbrin was soaked in PBS for at least two
ours before cutting it into two rectangular sheets (6 mm × 4 mm,
enceforth referred to as ﬁbrin scaffolds) using a razor blade
nder stereomicroscope observation. The ﬁbrin scaffolds were
ubsequently sterilised overnight at 4 ◦C in a PBS solution con-
aining 1% chloroform (Fisher Scientiﬁc). The scaffolds were then
ashed repeatedly with large volumes of sterile PBS for at least
our days to remove any trace of the chloroform and crosslinking
eagents.
.2. MSC  culture and plating onto a ﬁbrin scaffold
Rat GFP+ bone marrow-derived MSCs were isolated previously
19]. The cells were grown in vitro in vented T75 tissue culture ﬂasks
Asahi Glass Co. Ltd). Dulbecco’s modiﬁed eagle’s medium (DMEM,
nvitrogen) containing 10% fetal calf serum (Invitrogen), penicillin,
treptomycin, and amphotericin B (100 units, 0.1 mg,  and 0.25 g
espectively; Sigma–Aldrich) was used as the culture media. Cells
ere passaged whenever they became 90% conﬂuent. The MSCs
ere detached from the culture ﬂask using 0.05% trypsin-EDTA in
BSS (without Ca2+ or Mg2+, Invitrogen). When plating the cells
nto a ﬁbrin scaffold, a suspension of MSCs in media was pre-
ared. A sterile ﬁbrin scaffold was pinned to a cell strainer (BD
iosciences) using stainless steel minutien pins (0.1 mm diame-
er/10 mm length, InterFocus) and submerged in 7.5 mL  of culture
edia contained within one well of a six well plate (Nunc). 700,000
ells were then added to the media on top of the scaffold and the
ells were allowed to adhere and proliferate for approximately 24 h
n a 37 ◦C incubator (containing 5% CO2).Letters 569 (2014) 12–17 13
2.3. Lesioning of rat spinal cord and application of MSCs
All procedures were performed in compliance with the UK Ani-
mals (Scientiﬁc procedures) Act 1986 and institutional guidelines.
Female Sprague Dawley rats (200–250 g) were deeply anesthetised
with 1–2% isoﬂurane in a mixture of 25% nitrous oxide and 50% oxy-
gen. A spinal cord injury was performed as previously described
[20]. Brieﬂy, a C4 laminectomy was  performed to expose the spinal
cord. In this case, the laminectomy extended to most of C3 and C5
vertebrae in order to accommodate the scaffold. The dura overly-
ing the spinal cord at the C3, C4, and C5 levels was removed. A cut
was made with the tips of sharpened ﬁne forceps (Dumont No. 5)
inserted 2 mm in depth into the spinal cord parenchyma spanning
the gap between the dorsal root entries. The injury included the
descending dorsal corticospinal tracts and the ascending sensory
dorsal columns [21]. Four animals received an injection of MSCs,
4 L of cells (4.3 × 106 cells/mL) was  injected directly into the lesion
site through a pulled glass capillary needle with a tip diameter of
approximately 100 m (Harvard Instruments) at a rate of 6 L/h.
Three animals received MSCs via ﬁbrin scaffold, the scaffold was
unpinned from the cell strainer (pulling the pins out through the
bottom of the strainer) and lifted using a paintbrush, then laid
over top of the lesion site (cell-side down). Both the scaffold and
injection contained approximately the same number of cells. Quan-
tiﬁcation of the number of cells growing on ﬁbrin scaffolds after
24 h of incubation was  done in order to determine the number of
cells to inject (data not shown).
2.4. Immunohistochemical staining of GFP and GAP43 in lesioned
spinal cord treated with GFP+ MSCs
Animals were sacriﬁced three weeks after MSC  treatment/injury
and transcardially perfused with 4% PFA. The spinal cord from
C2-C6 was dissected out of each perfused animal and post-ﬁxed
overnight in 4% PFA (Sigma–Aldrich) and then cryoprotected in
30% sucrose (Sigma–Aldrich). The spinal cord tissue was then
embedded in O.C.TTM Compound (Sakura Finetek) and cryosec-
tioned longitudinally on a Leica CM 3050S cryostat. 20 m thick
sections were mounted on a series of SuperFrost® glass slides
(VWR), such that each slide possessed sections from through-
out the spinal cord. Slides were stored at −20 ◦C. Slides from
each animal were stained with either chicken anti-GFP anti-
body (1:1000 dilution, Millipore) and mouse anti-GAP43 antibody
(1:500 dilution, Millipore) or chicken anti-GFP antibody and
rabbit anti-neuroﬁlament heavy chain antibody (1:500 dilution,
ENZO). Antibody dilutions were made in PBS containing 10%
heat-inactivated horse serum (Sigma–Aldrich) and 0.2% Triton
X–100 (Sigma–Aldrich). Primary antibodies were labelled with
anti-chicken Alexa Fluor 488 antibody (1:1000 dilution, Invit-
rogen), anti-mouse Alexa Fluor 555 antibody (1:1000 dilution,
Invitrogen), and anti-rabbit Alexa Fluor 555 antibody (1:1000 dilu-
tion, Invitrogen).
3. Results
3.1. Delivery of MSCs to spinal cord via ﬁbrin scaffold
Thin sheets of EDC-ﬁbrin were created for use as cell scaffolds
(Fig. 1A). MSCs were found to adhere to and grow on the surface
of the scaffolds in vitro (Fig. 1B). The cells were implanted in vivo
as a single layer, growing on the surface of the ﬁbrin. After implan-
tation, the MSCs proliferated between the ﬁbrin scaffold and the
spinal cord to form a multi-layered graft. The cells completely ﬁlled
the lesion site and grew over top of a signiﬁcant amount of unle-
sioned spinal cord tissue ﬂanking the injury (Fig. 2A). The length
14 A.J.T. Hyatt et al. / Neuroscience Letters 569 (2014) 12–17
Fig. 1. EDC-ﬁbrin scaffold. (A) Suspended in the air with a paintbrush. Scaffold dimensions are 6 mm × 4 mm.  (B) GFP+ MSCs growing on the surface of a scaffold in vitro.
Scale bar represents 200 m.
Fig. 2. MSC graft delivered to injured spinal cord via ﬁbrin scaffold (3 weeks post-implantation). (A) Entire graft stained with anti-GFP antibody. Asterisk indicates the lesion
site.  (B and C) Magniﬁed area of graft (designated by small box in A), showing GAP43 positive neurites (red) entering the MSC  graft (green). The arrow points to a neurite
that  changes direction after entering the graft. (D and E) Magniﬁed area of graft (designated by large box in A), shows GAP43 positive neurites growing within the MSC graft.
Arrows point toward neurites and serve as reference points. Scale bars represent: 500 m (A), 50 m (B and C), 200 m (D and E).
A.J.T. Hyatt et al. / Neuroscience Letters 569 (2014) 12–17 15
Fig. 3. MSC  graft delivered to injured spinal cord via intraspinal injection (3 weeks post-injection). (A) An entire graft stained with anti-GFP antibody. (B) Magniﬁed area of
graft  (designated by box in A). Neurites stained for neuroﬁlament (C and D) and GAP43 (E and F) growing within a graft. Arrows point toward neurites and serve as reference
points.  Scale bars represent: 500 m (A), 100 m (B–D), 50 m (E and F).
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of the MSC  graft (after three weeks in vivo) was comparable to the
ength of the initial ﬁbrin scaffold (5.82 ± 0.92 mm  versus 6 mm;
ean ± SD, N = 3). The scaffold remained intact in vivo for at least
hree weeks. The three animals that received MSCs via scaffold
nd four animals that received MSCs via injection were assessed
ualitatively for MSC  orientation and neurite outgrowth. At the
oundary between the MSC  graft and the host spinal cord, GAP43+
eurites were found to migrate into the MSC  graft and change their
irection of growth, conforming to the architecture of the graft;
ome neurites were seen to enter the graft at a signiﬁcant distance
rom the lesion site (Fig. 2B and C). The graft was mainly composed
f longitudinally-aligned layers of MSCs, neurites found within thegraft mostly conformed to this architecture (Fig. 2D and E). The
MSCs that ﬁlled in the lesion site did show less organized longitu-
dinal architecture than the rest of the graft; as expected the axons
that entered this region of the graft also showed more variability
in their direction of growth.
3.2. Delivery of MSCs to spinal cord via intraspinal injectionMSCs injected into the spinal cord remained viable and inte-
grated into the tissue, completely ﬁlling the lesion site. After three
weeks in vivo, the cells were found to be largely restricted to the
injury site (Fig. 3A). The longitudinal length of an injected graft was
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.54 ± 1.33 mm (mean ± SD, N = 4). This is signiﬁcantly less than the
ength of grafts formed when a ﬁbrin scaffold was used to deliver
he MSCs (p < 0.005; unpaired, two-tailed T-Test). Many of the MSCs
elivered via injection adopted an orientation that was  perpendic-
lar to the plane of the spinal cord, many cells also assumed random
rientations (Fig. 3B). Host neurites were found to migrate into the
SC  graft (Fig. 3C–F). Many neuroﬁlament+ neurites (Fig. 3C and D)
nd GAP43+ neurites (Fig. 3E and F) found within an injected graft
ere seen to grow perpendicular to the plane of the spinal cord, in
ccordance with the architecture of the MSCs.
. Discussion
In animal models of spinal cord injury, intraspinal injection is
 common method of delivering therapeutic cells. It is simple and
ften effective at engrafting cells. However, there are some con-
erns that this method may  cause additional damage to the spinal
ord [16]. The purpose of this study was to determine if a biodegrad-
ble ﬁbrin scaffold could be used instead of direct injection to
eliver MSCs.
A novel formulation of ﬁbrin, crosslinked with EDC, was  devel-
ped for use as the scaffolding material. Fibrin is a clinically
pproved material that is routinely used in human patients. EDC
s a zero-length crosslinker that has been used extensively with
ollagen [22–24]. Recently, artiﬁcial corneas made from EDC-
rosslinked collagen entered human clinical trials [25]. We  found
hat it was possible to create thin sheets of EDC-crosslinked ﬁbrin,
hich supported the attachment and proliferation of MSCs on their
urface. The scaffolds were rigid enough to maintain their shape
hile handling and ﬂexible enough to conform to the spinal cord
pon implantation. Scaffolds were found to slowly degrade in vivo,
asting approximately six weeks.
MSCs delivered via scaffold formed stratiﬁed layers that bridged
he lesion site. The cells had no preferred orientation prior to
mplantation. It is possible that the cells re-orient after implan-
ation into a more organized longitudinal direction. Schwann cell
tudies utilizing matrices have previously shown that these cells
ill orient longitudinally relative to the spinal cord [26,27]. Fur-
hermore, Hofstetter et al. showed that MSCs can form parallel
ords that orient longitudinally in the spinal cord [7]. Another pos-
ibility is that the MSCs remain randomly oriented, and as they
roliferate from a single layer in vitro into a multi-layered graft
n vivo, they create longitudinally-aligned layers of cells. If we were
o view the MSCs within each layer from a top-down view, we may
nd that the cells look disorganized, similar to that seen in vitro
Fig. 1B). We  can only conclude from our data that the layers of
ells are longitudinally oriented.
The length of the MSC  graft corresponded to the length of the
brin scaffold; therefore, it may  be possible to control how far the
ellular bridge extends past the edges of the lesion site by simply
hanging the length of the scaffold. In the present study, a signif-
cant amount of unlesioned spinal cord tissue, ﬂanking the injury
ite, was present beneath the MSC  graft. Host neurites within this
nlesioned tissue were found to migrate into the graft. In addition,
he layered architecture of the MSCs appeared to promote longitu-
inal growth of neurites within the graft. Further investigation will
e needed to determine whether these factors (i.e. graft contact
ith unlesioned tissue and the layered architecture of the MSCs)
acilitate regeneration of damaged spinal cord.
In contrast to MSCs delivered by the scaffold, MSCs delivered via
njection largely remained restricted to the lesion site and were not
een to contact signiﬁcant amounts of unlesioned spinal cord tis-
ue. The cellular bridges formed by MSCs delivered by the scaffolds
ere nearly four times longer than the grafts formed by injected
ells. Furthermore, the orientation of the engrafted cells differed
[
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signiﬁcantly between the two  groups. Whereas MSCs delivered via
scaffold formed longitudinally-aligned layers, the MSCs delivered
via injection often oriented perpendicular to the plane of the spinal
cord. Neurites found within the injected cell graft also grew perpen-
dicular to the plane of the spinal cord. Previous research has shown
that regenerating neurites will enter MSC  grafts within the spinal
cord and use the orientation of the MSCs as a guide to determine
the direction of growth [7]. Furthermore, the chaotic architecture of
cells often seen within a spinal cord lesion site promotes haphazard
orientations of regenerating axons within the lesion; disoriented
axons are unlikely to facilitate much recovery [16,28].
It remains to be seen whether the differences between the two
types of MSC  graft (i.e. the injected graft and the graft delivered by
the scaffold) affect the ability of the spinal cord to regenerate fol-
lowing injury. It would also be useful to evaluate the ﬁbrin system
using a contusion injury model instead of the vertical cut model
used in this study. It is possible that the cut injury model resulted
in greater inﬁltration of ﬁbroblasts and the formation of a vertical
scar, which could have inﬂuenced the orientation of the MSCs. We
consider the ﬁbrin delivery system promising in many regards, par-
ticularly with respect to MSC  orientation and neurite outgrowth,
but it will require further studies to validate any advantages over
existing delivery methods.
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